For investors in biotech stocks, it can be hard to find promising long-term investment opportunities. Clinical trials can take years and millions of dollars to complete, and most investors are not willing to wait such a long time for a major catalyst. However, for those investors that are, I recommend looking at Syndax Pharmaceuticals (NASDAQ:SNDX). Syndax has multiple products in various phases of clinical development, and has the knowledge to see them through to FDA approval. Syndax will also have the financial resources needed to see these products through to FDA approval.
The biggest driver of growth for Syndax moving forward will be its pipeline. The pipeline should help to provide investors with stable returns for their...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|